Global Live Attenuated Vaccines Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Live Attenuated Vaccines Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
An attenuated vaccine is a vaccine created by reducing the virulence of a pathogen, but still keeping it viable (or "live"). Attenuation takes an infectious agent and alters it so that it becomes harmless or less virulent. These vaccines contrast to those produced by "killing" the virus (inactivated vaccine).
Live Attenuated Vaccines report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Live Attenuated Vaccines market is projected to reach US$ 40390 million in 2034, increasing from US$ 25940 million in 2022, with the CAGR of 6.1% during the period of 2024 to 2034. Demand from Hospitals and Clinics are the major drivers for the industry.
Examples of live attenuated) vaccines includeViralmeasles vaccine, mumps vaccine, rubella vaccine and live attenuated influenza vaccine (the seasonal flu nasal spray and the 2009 H1N1 flu nasal spray), etc; BacterialBCG vaccine, oral typhoid vaccine and epidemic typhus vaccine.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Live Attenuated Vaccines market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
GlaxoSmithKline
Merck
Pfizer
Astellas Pharma
Johnson & Johnson
CSL
Sanofi
Serum Institute Of India
Segment by Type
Bacterial
Viral
Hospitals
Clinics
Research Institutes
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Live Attenuated Vaccines market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Live Attenuated Vaccines, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Live Attenuated Vaccines industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Live Attenuated Vaccines in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Live Attenuated Vaccines introduction, etc. Live Attenuated Vaccines Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Live Attenuated Vaccines market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Live Attenuated Vaccines report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Live Attenuated Vaccines market is projected to reach US$ 40390 million in 2034, increasing from US$ 25940 million in 2022, with the CAGR of 6.1% during the period of 2024 to 2034. Demand from Hospitals and Clinics are the major drivers for the industry.
Examples of live attenuated) vaccines includeViralmeasles vaccine, mumps vaccine, rubella vaccine and live attenuated influenza vaccine (the seasonal flu nasal spray and the 2009 H1N1 flu nasal spray), etc; BacterialBCG vaccine, oral typhoid vaccine and epidemic typhus vaccine.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Live Attenuated Vaccines market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
GlaxoSmithKline
Merck
Pfizer
Astellas Pharma
Johnson & Johnson
CSL
Sanofi
Serum Institute Of India
Segment by Type
Bacterial
Viral
Segment by Application
Hospitals
Clinics
Research Institutes
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Live Attenuated Vaccines market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Live Attenuated Vaccines, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Live Attenuated Vaccines industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Live Attenuated Vaccines in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Live Attenuated Vaccines introduction, etc. Live Attenuated Vaccines Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Live Attenuated Vaccines market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices